Search Results - "Thomaidou, D."

Dual targeting of RANKL/RANK pathway and HER-2 as a novel treatment strategy in HER-2 positive (+) breast carcinomas (BC) by Zoi, I., Xingi, E., Thomaidou, D., Papavassiliou, A.G., Karamouzis, M.V.

Get full text

Mining the effect of the neonicotinoids imidacloprid and clothianidin on the chemical homeostasis and energy equilibrium of primary mouse neural stem/progenitor cells using metabolomics by Fotopoulou, E., Lykogianni, M., Papadimitriou, E., Mavrikou, S., Machera, K., Kintzios, S., Thomaidou, D., Aliferis, Κ.Α.

“…The projection of plant protection products' (PPPs) toxicity to non-target organisms at early stages of their development is challenging and demanding. Recent…”
Get full text

Schwann cell transplantation for CNS repair by Lavdas, A A, Papastefanaki, F, Thomaidou, D, Matsas, R

“…Demyelination occurs in several central nervous system (CNS) disorders, including multiple sclerosis, viral infection and spinal cord injury and can result in…”
Get more information

Grafts of Schwann cells engineered to express PSA-NCAM promote functional recovery after spinal cord injury by Papastefanaki, Florentia, Chen, Jian, Lavdas, Alexandros A., Thomaidou, Dimitra, Schachner, Melitta, Matsas, Rebecca

“…Schwann cells (SCs) are among the most attractive cellular candidates for the development of remyelination therapies for CNS lesions. Yet, their integration in…”
Get full text

Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101 by Grimm, M-O., Oya, M., Choueiri, T., Schmidinger, M., Quinn, D.I., Gravis-Mescam, G., Marseille, E., Van Den Eertwegh, A.J.M., Di Pietro, A., Mariani, M., Wang, J., Thomaidou, D., Albiges, L.

Get full text

Gap junctions in the adult cerebral cortex: Regional differences in their distribution and cellular expression of connexins by Nadarajah, B., Thomaidou, D., Evans, W.H., Parnavelas, J.G.

“…Gap junctions are membrane channels that mediate electrical and metabolic coupling between adjacent cells. Immunocytochemical analysis by using a panel of…”
Get full text

1360P Updated patient-reported outcomes from the CROWN study: Analyses in first-line ALK+ patients with (w) and without (w/o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs) by Liu, G., Zhou, Q., Solomon, B.J., Le, H., Reisman, A., Thomaidou, D., Toffalorio, F., Mazieres, J.

Get full text

Emx1 is a Marker for Pyramidal Neurons of the Cerebral Cortex by Chan, C.-H., Godinho, L. N., Thomaidou, D., Tan, S.-S., Gulisano, M., Parnavelas, J. G.

“…The homeobox-containing gene, Emx1, a mouse homologue of Drosophila empty spiracles, is specifically expressed in the developing telencephalic cortex. It has…”
Get full text

111P Real-world treatment modification of first-line axitinib + pembrolizumab in patients with metastatic renal cell carcinoma (mRCC) by Zakharia, Y., Thomaidou, D., Li, B., Siu, G., Levin, R., Vlahiotis, A., Zanotti, G.

Get full text

75P Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib + checkpoint inhibitor (CPI) therapy by Huynh, L., Du, S.S., Chang, R., Pi, S., Sundaresan, S., Duh, M.S., Thomaidou, D., Zanotti, G., Zakharia, Y.

Get full text

PCR234 Patient and Oncologist Preferences for Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer (ALK+ aNSCLC) Tyrosine Kinase Inhibitors (TKIs) Treatments in the First Line (1L) Setting by Le, H, Coulter, J, Cappelleri, J, Lu, H, Quaife, M, Meginnis, K, Fernandez, G, Culver, KW, Vaghela, S, Thomaidou, D, Stinchcombe, T

Get full text

979P Long-term intracranial safety and efficacy analyses from the phase III CROWN study by Bearz, A., Felip, E., Mazieres, J., de Marinis, F., Bauer, T., Polli, A., Messina, R., Thurm, H., Thomaidou, D., Mok, T.S.K., Solomon, B.J.

Get full text

66PDual targeting of RANKL/RANK pathway and HER-2 as a novel treatment strategy in HER-2 positive (+) breast carcinomas (BC) by Zoi, I, Xingi, E, Thomaidou, D, Papavassiliou, A G, Karamouzis, M V

Get full text

EE150 Resource Utilisation in Non-Small Cell Lung Cancer With Brain/CNS Metastases in Europe, Asia, US and Brazil by Bailey, H, Last, M, Forshaw, C, Chandrasekar, S, Foley, G, Burlison, H, Wong, CH, Iadeluca, L, Krulewicz, S, Wiltshire, R, Thomaidou, D, Duncan, K

Get full text

665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101 by Grimm, M-O., Oya, M., Choueiri, T.K., Schmidinger, M., Quinn, D.I., Gravis Mescam, G., Verzoni, E., Van den Eertwegh, A.J.M., di Pietro, A., Mariani, M., Wang, J., Thomaidou, D., Albiges, L.

Get full text

Identification of a novel neuron-specific surface antigen in the developing nervous system, by monoclonal antibody 4C5 by Thomaidou, D, Patsavoudi, E

“…Monoclonal antibody 4C5 was obtained after immunization of Balb/c mice with a crude membrane preparation derived from the brains of 15-day-old rat embryos. As…”
Get more information

Characterization and localization of the BM88 antigen in the developing and adult rat brain by Patsavoudi, E, Merkouri, E, Thomaidou, D, Sandillon, F, Alonso, G, Matsas, R

“…Monoclonal antibody BM88 identifies a neuron-specific antigen (BM88 antigen) present in the central and peripheral nervous system of the pig (Patsavoudi et…”
Get more information

Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC) by Albiges, L., Rini, B.I., Haanen, J B A G, Motzer, R.J., Kollmannsberger, C.K., Negrier, S., Nole, F., Bedke, J., Bilen, M.A., Nathan, P., Tomita, Y., Huang, B., Ching, K.A., Chudnovsky, A., Robbins, P.B., di Pietro, A., Thomaidou, D., Choueiri, T.K.

Get full text

908PD - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC) by Albiges, L., Rini, B.I., Haanen, J B A G, Motzer, R.J., Kollmannsberger, C.K., Negrier, S., Nole, F., Bedke, J., Bilen, M.A., Nathan, P., Tomita, Y., Huang, B., Ching, K.A., Chudnovsky, A., Robbins, P.B., di Pietro, A., Thomaidou, D., Choueiri, T.K.

“…On the basis of noninferiority outcomes for pts with metastatic disease who received S vs pts who underwent uCN followed by S (Mejean NEJM 2018), the role of…”
Get full text

Developmental expression and functional characterization of the 4C5 antigen in the postnatal cerebellar cortex by Thomaidou, D, Dori, I, Patsavoudi, E

“…The monoclonal antibody 4C5 recognizes a neuron-specific surface antigen (4C5 antigen) in the CNS and PNS of the rat. In the present study we investigated the…”
Get more information